Speciality: Dermatology
Description:
A warm welcome to all the medical professionals in this interesting session on Role of Biologics in Psoriasis
Biologics have revolutionized the treatment of psoriasis, offering targeted therapies that specifically address the underlying mechanisms of the disease. Unlike traditional systemic treatments, which can have broad immunosuppressive effects, biologics target specific components of the immune system involved in psoriasis pathogenesis. This precision has led to significant improvements in efficacy and safety for patients with moderate to severe psoriasis. The most commonly used biologics in psoriasis treatment include TNF inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. These biologics have demonstrated remarkable success in reducing psoriatic lesions, improving skin clearance, and enhancing the quality of life for patients. Clinical trials and real-world studies have shown that biologics can achieve rapid and sustained remission in many patients, with some experiencing near-complete resolution of their symptoms.
Therefore, get an overall knowledge of updated Role of Biologics in Psoriasis
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation